131 Oyster Point Boulevard
Suite 600
South San Francisco, CA 94080
United States
415 231 5660
https://www.alector.com
版塊: Healthcare
行業: Biotechnology
全職員工: 244
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Arnon Rosenthal Ph.D. | Co-Founder, CEO & Director | 1.06M | 無 | 1956 |
Dr. Saraswati Kenkare-Mitra Ph.D. | President and Head of Research & Development | 1.29M | 無 | 1968 |
Dr. Marc Grasso M.D. | CFO, Principal Financial Officer & Principal Accounting Officer | 728.71k | 無 | 1974 |
Dr. Gary Romano M.D., Ph.D. | Chief Medical Officer | 752.17k | 無 | 1962 |
Mr. Peter Heutink Ph.D. | Chief Scientific Officer | 無 | 無 | 無 |
Katie Hogan | Senior Director of Corporate Communication & Investor Relations | 無 | 無 | 無 |
Ms. Danielle Pasqualone J.D., Ph.D. | General Counsel | 無 | 無 | 無 |
Ms. Clare Hunt M.B.A. | Chief People Officer | 無 | 無 | 無 |
Ms. Kristina Cutter M.P.H. | Chief Regulatory, Pharmacovigilance, & Quality Assurance Officer | 無 | 無 | 無 |
Ms. Virginia DeJesus-Rueff M.B.A. | Chief of Staff & Head of Strategy | 無 | 無 | 無 |
Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
截至 2024年5月1日 止,Alector, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中:9;董事會:5;股東權利:8;現金賠償:7。